Tag:

Treatments

The director highlights the resilience of the CF community in the face of the pandemic, the historical access to Trikafta in Quebec, the evolution of the VAFK team and the organization's renewed commitment to supporting members, in view of the 40th anniversary celebrations in 2025.

The data suggests that, despite common inflammatory mechanisms, people with cystic fibrosis may present a form of COVID-19 that is often less severe than expected, possibly thanks to cellular characteristics of CF and the potential protective effect of CFTR modulators.

A clear reminder of the recommended order to optimize the effectiveness of inhaled treatments and medications for people living with cystic fibrosis, from bronchodilators to antibiotics.

This 2022 update presents the major advances in cystic fibrosis research, marked by the arrival of CFTR modulators (ETI/Trikafta), their major benefits, emerging clinical challenges and research paths for ineligible people.

This article takes stock of the possible links between CFTR modulators, in particular Trikafta, and mental health, by exploring indirect psychological effects, possible biological mechanisms, drug interactions, and the importance of individualized follow-up.

This article explores the psychological and identity upheavals experienced by people with cystic fibrosis in the Trikafta era, between immense hope, social pressures, past griefs and the need to reinvent themselves in the face of a suddenly possible future.